Posts Tagged ‘Featured’
Glycovax Pharma and Université Laval to develop innovative inhibitors targeting galectin-3
Idiopathic pulmonary fibrosis (IPF) affects approximately 15,000 people in Canada, 100,000 in the United States, and 200,000 in Europe, while nonalcoholic steatohepatitis (NASH) affects approximately 38 million Americans, 10 million Europeans, and 1.5 million Canadians. Professor Denis Giguère, from the Department of Chemistry at Université Laval, an expert in carbohydrate chemistry and complex molecule design,…
Read MoreGlycovax, the NRC and the Université de Montréal develop a vaccine against the bacterium Pseudomonas aeruginosa (Pa), with support from CQDM
Respiratory diseases—which develop particularly in hospitals, such as those resulting from Pa infections—remain a scourge for which there is currently no effective vaccine. Often resistant to antibiotics, Pa infection is a leading cause of hospital-acquired illness and of infections that are sometimes fatal in people with cystic fibrosis. Glycovax Pharma has optimized manufacturing of the…
Read MoreGlycovax Pharma Granted NRC Licence to Develop Pseudomonas aeruginosa Vaccine
Glycovax Pharma has been granted a strategic licence by the NRC to develop a semisynthetic vaccine targeting Pseudomonas aeruginosa — a high-priority pathogen according to the WHO, responsible for severe hospital-acquired infections. This vaccine aims to protect vulnerable individuals, especially those living with cystic fibrosis. Continue reading…
Read More